Hims & Hers Health
HIMS
$33.78
+6.03%
Hims & Hers Health, Inc. is a telehealth platform that connects patients with healthcare providers for treatments in areas such as erectile dysfunction, hair loss, skin care, mental health, and weight loss, offering both prescription and over-the-counter products through a direct-to-consumer model. As a disruptor in the digital health space, it has built a subscriber base of over 2 million and operates across all 50 states and select European markets, distinguishing itself with a vertically integrated platform that includes provider networks, electronic medical records, and cloud pharmacy fulfillment. Currently, the stock is under scrutiny as the company navigates a strategic pivot toward weight-loss drugs, which has boosted revenue but pressured profitability, while a recent debt-funded expansion and convertible offering have raised concerns about dilution and financial risk. The investor narrative is dominated by debates over the sustainability of its growth, the impact of rising competition in the GLP-1 market, and the balance between aggressive expansion and near-term earnings.…
HIMS
Hims & Hers Health
$33.78
Related headlines
Investment Opinion: Should I buy HIMS Today?
Based on the analysis, the recommendation is a Hold. The stock is currently trading at $28.15, with an average analyst target of $31.15, implying a modest 10.7% upside. The consensus rating is 'Hold' with a mean score of 2.8, reflecting uncertainty about the company's ability to navigate its current challenges. The thesis is that while the GLP-1 partnership provides a potential growth catalyst, the sharp revenue deceleration and net loss in Q1 2026 warrant caution.
Sign up to view all
HIMS 12-Month Price Forecast
The AI assessment is neutral with medium confidence. The company's growth has decelerated sharply, and profitability has deteriorated, but the GLP-1 partnership provides a potential catalyst. The stock is trading at a forward P/S of 1.73x, which is not demanding, but the high debt and dilution risk are concerning. The stance would upgrade to bullish if revenue growth re-accelerates above 20% and gross margins stabilize above 60%, or if the stock price drops below $20, offering a more attractive entry point. It would downgrade to bearish if revenue growth turns negative or if the company announces additional dilutive financing.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Hims & Hers Health's 12-month outlook, with a consensus price target around $30.85 and implied upside of -8.7% versus the current price.
Average Target
$30.85
0 analysts
Implied Upside
-8.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$23 - $42
Analyst target range
The target price range spans from a low of $23.00 to a high of $42.00, representing a wide spread of 82.6% from low to high, indicating high uncertainty about the company's future. The low target of $23.00 implies a downside of 18.3% from the current price, likely reflecting concerns about continued margin compression, competitive pressures in the weight-loss market, and potential dilution from the convertible debt offering. The high target of $42.00 implies an upside of 49.2%, which would require a successful execution of the GLP-1 strategy and a return to robust growth. The wide range suggests that analysts have divergent views on the company's ability to navigate its current challenges, and the recent downgrades and cautious commentary from firms like B of A Securities highlight the risk. Given the lack of strong buy consensus and the recent negative news flow, the stock is likely to remain volatile, and investors should brace for continued uncertainty.
Bulls vs Bears: HIMS Investment Factors
The bull case for Hims & Hers rests on its strong gross margins, strategic GLP-1 partnership, and positive free cash flow, which could drive a recovery in growth and profitability. However, the bear case is compelling due to the sharp revenue deceleration, net loss, high debt, and dilution risk, which have led to significant underperformance and a Hold consensus. Currently, the bearish evidence is stronger, as the company's growth trajectory has stalled and profitability has deteriorated. The most critical tension is whether the GLP-1 partnership can reignite growth and restore margins, or whether competitive pressures and rising costs will continue to erode value. If the partnership succeeds, the stock could see significant upside; if not, the downside to the 52-week low of $13.74 is substantial.
Bullish
- Revenue Growth Still Positive: Q1 2026 revenue reached $608.1 million, up 3.77% year-over-year, indicating the business continues to expand despite a sharp deceleration from the 51.5% growth in Q1 2025. The absolute revenue level remains high, and the company has maintained a subscriber base of over 2 million, providing a stable foundation for future growth.
- Strong Gross Margin: Gross margin for Q1 2026 was 49.38%, down from 73.5% in Q1 2025 but still robust for a telehealth platform. The trailing twelve-month gross margin is 73.8%, reflecting the company's ability to generate significant gross profit from its direct-to-consumer model, which can support future profitability improvements.
- Strategic GLP-1 Partnership: The Novo Nordisk partnership, announced in March 2026, removes a major legal overhang and provides a clear growth path in the weight-loss drug market. This deal could drive significant revenue upside, as the GLP-1 market is expanding rapidly, and Hims & Hers is well-positioned to distribute these drugs through its telehealth platform.
- Positive Free Cash Flow: The company generated $75.8 million in trailing twelve-month free cash flow, indicating that despite the net loss in Q1 2026, the underlying business is still generating cash. This provides financial flexibility to fund growth initiatives without relying solely on external financing.
Bearish
- Sharp Revenue Growth Deceleration: Revenue growth slowed dramatically to 3.77% year-over-year in Q1 2026, down from 51.5% in Q1 2025. Sequential revenue declined from $617.8 million in Q4 2025 to $608.1 million in Q1 2026, signaling potential market saturation or intensifying competition, which is a major red flag for a growth stock.
- Net Loss and Margin Compression: The company reported a net loss of $92.1 million in Q1 2026, a stark contrast to the $49.5 million net income in Q1 2025. Operating margin turned negative at -2.7%, and gross margin fell to 49.4% from 73.5%, reflecting the high costs associated with the weight-loss drug pivot and increased competition.
- High Debt and Dilution Risk: The debt-to-equity ratio stands at 2.07, and the recent $350 million convertible debt offering threatens significant shareholder dilution. This debt-funded expansion increases financial risk, and the market has reacted negatively, with the stock dropping sharply on the announcement.
- Underperformance and High Volatility: The stock is down 40.27% over the past year, significantly underperforming the S&P 500's gain of 20.37%. With a beta of 2.415, the stock is 141.5% more volatile than the market, amplifying downside risk in a downturn.
HIMS Technical Analysis
Hims & Hers is in a pronounced downtrend over the past year, with the stock down 40.27% over the last 12 months, significantly underperforming the S&P 500, which gained 20.37% in the same period. The current price of $28.15 sits at 43.1% of its 52-week range, calculated as (28.15 - 13.74) / (65.30 - 13.74), indicating it is closer to the lower end of its yearly range. This positioning suggests the stock is in a bearish phase, with the 52-week low of $13.74 representing a potential support level, while the high of $65.30 marks a distant resistance. The stock's beta of 2.415 implies it is 141.5% more volatile than the market, amplifying both downside and upside moves.
Beta
2.42
2.42x market volatility
Max Drawdown
-78.1%
Largest decline past year
52-Week Range
$14-$65
Price range past year
Annual Return
-23.2%
Cumulative gain past year
| Period | HIMS Return | S&P 500 |
|---|---|---|
| 1m | +6.6% | +2.5% |
| 3m | +42.2% | +2.7% |
| 6m | +116.1% | +11.1% |
| 1y | -23.2% | +20.5% |
| ytd | +1.1% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HIMS Fundamental Analysis
Revenue growth has decelerated sharply, with the most recent quarter (Q1 2026) showing revenue of $608.1 million, up only 3.77% year-over-year, a dramatic slowdown from the 51.5% growth seen in Q1 2025 (when revenue was $586.0 million). This deceleration is concerning, especially as the company's pivot to weight-loss drugs was expected to drive higher growth, but the revenue trajectory suggests the market is becoming saturated or competition is intensifying. The multi-quarter trend shows revenue peaked at $617.8 million in Q4 2025, and the sequential decline to $608.1 million in Q1 2026 indicates a potential stagnation, which is a red flag for a growth stock.
Quarterly Revenue
$608104000.0B
2026-03
Revenue YoY Growth
+3.8%
YoY Comparison
Gross Margin
49.4%
Latest Quarter
Free Cash Flow
$75838000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HIMS Overvalued?
Given that the company reported a net loss of $92.1 million in Q1 2026, the trailing P/E ratio is not meaningful, so I selected the price-to-sales (P/S) ratio as the primary valuation metric. The trailing P/S ratio is 3.11x, while the forward P/S ratio (based on estimated revenue of $4.21 billion for 2026) is approximately 1.73x, implying the market expects significant revenue growth to justify the current valuation. The gap between trailing and forward P/S suggests that investors are pricing in a recovery in profitability, but the recent earnings miss and slowing growth cast doubt on these expectations.
PE
57.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 13x~90x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
45.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are elevated. The company reported a net loss of $92.1 million in Q1 2026, a sharp reversal from the $49.5 million profit in Q1 2025, driven by a collapse in gross margin from 73.5% to 49.4% and negative operating margin of -2.7%. The debt-to-equity ratio of 2.07 and the recent $350 million convertible offering increase financial leverage and dilution risk, which could pressure earnings per share. Revenue growth has decelerated to 3.77% year-over-year, and sequential revenue declined from $617.8 million to $608.1 million, indicating potential stagnation. The company's reliance on the weight-loss drug market, which is highly competitive and subject to pricing pressures, adds concentration risk. Free cash flow of $75.8 million is positive but thin relative to the company's market cap, limiting financial flexibility.
FAQ
The key risks of holding HIMS are: 1) Financial risk: high debt-to-equity of 2.07 and the recent $350 million convertible offering could lead to dilution and financial distress. 2) Competitive risk: the GLP-1 market is becoming crowded, with generic semaglutide from India and Novo Nordisk's higher-dose Wegovy increasing competition. 3) Macro risk: with a beta of 2.415, the stock is highly sensitive to interest rate changes and market volatility. 4) Company-specific risk: revenue growth has decelerated to 3.77% year-over-year, and the company reported a net loss of $92.1 million in Q1 2026, indicating operational challenges. The most severe risk is a continued decline in revenue and margins, which could push the stock to the 52-week low of $13.74.
The 12-month forecast for HIMS is uncertain, with a wide range of outcomes. In the bull case (25% probability), the stock could reach $35-$42, driven by successful GLP-1 execution and re-accelerating growth. In the base case (50% probability), the stock is expected to trade around $28-$32, in line with the analyst average target of $31.15. In the bear case (25% probability), the stock could fall to $14-$23, if growth stalls and losses continue. The most likely scenario is the base case, assuming the company stabilizes its growth and margins. However, the high uncertainty and recent negative trends suggest that investors should be prepared for significant volatility.
HIMS is trading at a trailing P/S ratio of 3.11x and a forward P/S of 1.73x, which is not excessive for a growth company but implies the market expects significant revenue growth. The forward P/E of 22.32x suggests the market is pricing in a return to profitability, but the recent net loss of $92.1 million in Q1 2026 casts doubt on that expectation. Compared to its own history, the stock is trading near the lower end of its 52-week range, indicating it is cheaper than it has been. However, the valuation is not a clear bargain given the decelerating growth and margin compression. The market is pricing in a recovery, but if growth continues to slow, the stock could be considered overvalued.
HIMS is not a good buy for most investors at the current price of $28.15, given the high uncertainty and recent negative trends. The stock has underperformed the market, with a 40.27% decline over the past year, and the consensus rating is 'Hold' with an average target of $31.15, implying only 10.7% upside. The biggest downside risk is a decline to the 52-week low of $13.74, representing a 51.2% loss. However, for aggressive investors with a high risk tolerance, the stock could be a speculative buy if they believe the GLP-1 partnership will reignite growth. The risk/reward is skewed to the downside in the near term, so it is better to wait for signs of stabilization before buying.
HIMS is more suitable for short-term trading than long-term investment, given its high volatility (beta of 2.415) and uncertain fundamentals. The stock has a beta of 2.415, making it highly sensitive to market swings, and its 40.27% decline over the past year shows it can be very volatile. The company is in a transition phase, with revenue growth decelerating and profitability deteriorating, which makes long-term earnings visibility low. For long-term investors, the stock could be considered if they believe the GLP-1 market will drive sustained growth, but they should be prepared for a holding period of at least 3-5 years to ride out the volatility. For short-term traders, the stock offers opportunities due to its high volatility, but the risk of loss is also high. A minimum holding period of 12 months is recommended to allow the GLP-1 strategy to show results.